Trial Profile
A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2021
Price :
$35
*
At a glance
- Drugs Osilodrostat (Primary)
- Indications Cushing syndrome
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
- 08 Dec 2021 New source identified and integrated Japan Pharmaceutical Information Center - Clinical Trials Information (JapicCTI153038)
- 07 Dec 2018 Status changed from active, no longer recruiting to completed.
- 07 Aug 2018 Planned End Date changed from 18 Jul 2018 to 29 Mar 2019.